
Lupin out-licenses eye disease biosimilar Latin America rights to SteinCares
Mumbai: Generics drug maker, Lupin has outlicensed its retinal disorder biosimilar ‘ranibizumab’ Latin America commercial rights (excluding Mexico and Argentina) to a healthcare company SteinCares. In a stock exchange filing Lupin announced that it has …